{"nctId":"NCT01993823","briefTitle":"Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis","startDateStruct":{"date":"2013-05"},"conditions":["Otomycosis"],"count":190,"armGroups":[{"label":"G238","type":"EXPERIMENTAL","interventionNames":["Drug: G238"]},{"label":"Clotrimazole","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Clotrimazole"]}],"interventions":[{"name":"G238","otherNames":[]},{"name":"Clotrimazole","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 years or older.\n* Clinical diagnosis of otomycosis where topical treatment is indicated.\n\nExclusion Criteria:\n\n* Other ear diseases.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Subjects With a Complete Response to Treatment","description":"Efficacy will be assessed primarily by evaluation of the fungal culture, and the sum of signs and symptom scores (pruritus, otalgia, otorrhea and aural fullness obstruction to be scored as 0=absent; 1= mild; 2=moderate; 3=severe). The primary efficacy variable is the proportion of subjects with a negative culture for fungus, AND a signs and symptom score of 0 on Day 24.\n\nResponse to the study treatment was classed according to the following definitions:\n\n* Complete response: Negative fungal culture or presumed eradication on day 24, and sum score for signs and symptoms = 0 on day 24.\n* Partial response: Negative culture or presumed eradication on day 24, and sum score for signs and symptoms = 1 or 2 on day 24.\n* No response: Positive culture on day 24 or negative culture or presumed eradication and sum score for signs and symptoms \\> 2 on day 24.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Signs/ Symptoms","description":"The secondary efficacy variables include:\n\n* Proportion of subjects with signs and symptoms score of \"0\" at Day 15\n* Proportion of subjects with signs and symptoms score of \"0\" at Day 24\n* Proportion of subjects with a negative culture for fungus or presumed eradication (mycological cure) on Day 24.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.55","spread":null},{"groupId":"OG001","value":"77.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.83","spread":null},{"groupId":"OG001","value":"86.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.63","spread":null},{"groupId":"OG001","value":"97.65","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mycological Study","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":89},"commonTop":[]}}}